The US Anti Cancer Drug Market Outlook to 2018
Demand of Oral Drugs to Drive Growth
Region:North America
Product Code:KR217
February 2014
152
About the Report
The report titled “The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth” provides a comprehensive analysis on the Anti Cancer Drug market in the US covering various aspects such as market size of the industry, market segmentation by Patented and Generic drugs, by type of cancer (blood cancer, breast cancer, lung cancer, pancreatic cancer, colon cancer) and by Oral and Injectable Drugs. The report also provides statistics and information on the government regulations, growth drivers and market shares of major players and brands in the market. The report also entails competitive landscape and profiles of the major players operating in the market. The future projections are included to provide an insight on the prospects in the US Anti Cancer Drug Market.
The US Anti Cancer Drug market is the largest market in the world which has registered a positive growth rate over the period. The rising growth rate can be attributed to an increasing number of drugs being approved by the United States Food and Drug Association along with the increasing number of cancer cases although many major drugs which lost their patent protection has hampered the growth of the market. The US Anti Cancer Drug Market has recorded a 5 year CAGR of 6.50% over the period. The sales of anti cancer drugs in the US grew from USD ~ billion in 2008 to USD ~ billion in 2013.
The Breast Cancer Drug Market is one of largest markets in terms of breast cancer drug sales with a global share of 59% and was valued at USD ~ billion in 2013. The breast cancer drug market though had a busy pipeline but has been mainly driven by sales of three major drugs namely Arimidex, Herceptin and Afinitor in recent years. Pancreatic cancer is one of the most researched segments as it cannot be diagnosed in a time leading to a fall in its survival rates. Avastin, Rituxan, Herceptin and Alimta were among the world’s top selling anti cancer drugs and each recorded sales above USD ~ million in the US in 2013.
The anti-cancer drug market of US is highly fragmented. The major players are continuously adopting diverse strategies in order to maintain their competitive edge especially when it comes to competition from generic drugs. Roche is the largest company in the US in terms of anti cancer drugs sales. The company held a market share of ~% and recorded sales of USD ~ million.
The US Anti Cancer Drug Market is expected to grow over the period at a CAGR of 29.41% with projected sales of USD ~ billion in 2018. It is estimated that the research and development productivity will increase and will trigger the growth in the market. The companies will focus on developing pharmaceutical drugs for personalized healthcare.
Key Topics Covered in the Report:
- The market size of the US anti cancer drug market on the basis of sales, number of drugs in development and number of drugs approved.
- The breast cancer, lung cancer, pancreatic cancer, colon cancer, blood and brain cancer drug market
- Market segmentation of the US anti cancer drug market on the basis of Type of Therapies, Orals and Injectables and by Generic and Patented Drugs
- Government Regulations in the US Anti Cancer Drug Market.
- Competitive landscape and detailed company profiles of the major players operating in the pesticides business in US
- Revenues of Major Players in US Anti Cancer Drugs Market.
- Future outlook and projections of US Anti Cancer Drugs Market, on the basis of anti cancer drug sales in the US.
Products
Cost Per Click, Cost Per Thousand Impression, Cost Per Action, Cost Per Completed View, Search and Social, Display, Lead Generation, Sponsorship Adver
Companies
Google, Yahoo, Bing, DMS, Facebook, Connect Ads, Net Advantage, Ikoo, Twitter, Shahid.net, Youtube, Flip Media, Prototype Interactive, Impact BBDO, 2Pure, Maktoob, Starcom Media Vest Group, Mindshare, Initiative, Universal Media, Drive Direct, OMD Media,
Table of Contents
1. Anti-Cancer Drugs Market Introduction
1.1. Global Scenario
1.2. Domestic Scenario
1.2.1. Overview
1.2.2. Research & Development Pipeline
Acquisition of Potential Compounds
Drug Screening and Pre Clinical Pharmacology
Clinical Trials
2. Prevalence of Different types of Cancers in the US
2.1. By Number of New Cancer Cases, 2008 -2013
2.2. By Major Types of Cancer, 2008-2013
Cases of Breast Cancer
Cases of Pancreatic Cancer
Cases of Colon Cancer
Cases of Lung Cancer
Cases of Blood Cancer
Cases of Brain Cancer
3. The US Anti-Cancer Drug Market Size
3.1. By Industry Sales, 2008-2013
3.2. By Number of Drugs Approved, 2008-2013
3.3. By Number of Cancer Drugs in Development, 2009 -2013
4. The US Anti-cancer Drug Market Segmentation
4.1. By Types of Cancers (Blood, Breast, Colon, Lung, brain and Pancreatic Cancer), 2010-2013
4.2. By Oral Drugs and Injectables, 2013
4.3. By Cost of Therapies, 2013
Chemotherapy
Stem Cell Transplant
Targeted therapy
Immunotherapy
Hormone Therapy
4.4. By Generic and Patented Drugs, 2013
5. The US Blood Cancer Drug Market Introduction
5.1. The US Blood Cancer Drug Market Size, 2008-2013
Sales of Major Brain-Cancer Treatment Drugs (Rituxan, Revlimid, Velcade, Sprycel, Vidaza), 2008-2013
5.2. By Treatment and Side Effects
Treatment Cycle
Side Effects
5.3. By Patents and Expiry
6. The US Breast Cancer Drugs Market Introduction
6.1. The US Breast Cancer Drugs Market Size, 2008-2013
By Sales of Major Cancer Drugs, 2008-2013
6.2. Treatment Process and Side Effects
Treatment Process
Side Effects
6.3. Patents and Expiry
7. The US Colon Cancer Drugs Market Introduction
7.1. The US Colon Cancer Drug Market Size, 2009-2013
Sales of Major Anti-Colon Cancer Drugs in The US, 2009-2013
7.2. Treatment and Side Effects
Treatment Cycle
Side Effects
7.3. Patents and Expiry
8. The US Brain Cancer Drugs Market Introduction
8.1. The US Brain Cancer Drugs Market Size, 2009-2013
Sales of Major Brain-Cancer Drugs in the US, 2009-2013
8.2. By Treatment and Side Effects
Treatment Cycle
Side Effects
8.3. By Patents and Expiry
9. The US Lung Cancer Drugs Market Introduction
9.1. The US Lung Cancer Drugs Market Size, 2008-2013
9.1.1. Sales of Major Cancer Drugs, 2008-2013
9.2. By Small Cell Lung Cancer and Non Small Cell Lung Cancer, 2013
9.3. Treatment Process and Side Effects
The Treatment Cycle of Lung Cancer
Side Effects
9.4. Patents and Expiry
10. The US Pancreatic Cancer Drugs Market Introduction
10.1. The US Pancreatic Cancer Drugs Market Size, 2008-2013
Sales of Major Pancreatic Cancer Drugs in the US, 2008-2013
10.2. Treatment Process and Side Effects
Treatment Cycle of Pancreatic Cancer
Side Effects
10.3. Patents and Expiry
11. Trends and Developments
12. Regulations in the US Anti-cancer Drug Market
Federal and State Regulations
13. SWOT Analysis
14. Growth Drivers and Restraints
14.1. Growth Drivers
14.2. Restraints
15. The US Anti-Cancer Drugs Industry Competitive Landscape
15.1. Market Share of Major Players by Revenue, 2010- 2013
15.2. Sales of Major Brands, Patents and Comparative Analysis of Major Pharmaceutical Companies, 2013
16. Company Profiles
16.1. Pfizer
16.1.1. Business Overview
16.1.2. Business Strategies
16.1.3. Financial Performance, 2009-2013
Anti-cancer Drug profile
Cancer Drug Pipeline
16.2. Novartis
16.2.1. Business Overview
16.2.2. Business Strategies
16.2.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug pipeline
16.3. Roche
16.3.1. Business Overview
16.3.2. Business Strategies
16.3.3. Financial Performance, 2010-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.4. Astra Zeneca
16.4.1. Business Overview
16.4.2. Business Strategies
16.4.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.5. Bristol-Myers Squibb
16.5.1. Business Overview
16.5.2. Business Strategies
16.5.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.6. Amgen
16.6.1. Business Overview
16.6.2. Business Strategies
16.6.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.7. Merck & Company
16.7.1. Business Overview
16.7.2. Business Strategies
16.7.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug pipeline
16.8. Celgene
16.8.1. Business Overview
16.8.2. Business Strategies
16.8.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.9. Sanofi-Aventis
16.9.1. Business Overview
16.9.2. Business Strategies
16.9.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.10. Eli Lilly
16.10.1. Business Overview
16.10.2. Business Strategies
16.10.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.11. GlaxoSmithKline
16.11.1. Business Overview
16.11.2. Business Strategies
16.11.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
17. The US Anti-Cancer Drug Market Future Outlook
Overall Market Predictions, 2014 - 2018
Role of the Government in the Future
Competition Expected to Evolve in Future
17.1. Cause and Effect Relationship between Independent and Dependent Factors
17.2. The US Anti-Cancer Drug Market Future Projections by Cancer Types, 2014-2018
17.3. Future Projections by Generic and Patented Drugs, 2018
18. Macro-Economic Factors Affecting the US Anti-Cancer Drugs Market
18.1. National Healthcare Spending, 2008-2018
18.2. Upper Class Population of the US, 2008-2018
18.3. Number of Oncologists in the US, 2008-2018
18.4. Consumer Expenditure on Healthcare, 2008-2018
19. Appendix
19.1. Market Definition
19.2. Abbreviations
19.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Final Conclusion
19.4. Disclaimer
Why Buy From Us?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.